The FDA has granted a CLIA waiver for FebriDx, enabling its use in over 300,000 U.S. point-of-care settings and potentially reaching 80 million patients annually, according to PHASE Scientific.
The 3-test panel detects antibodies for parasitic infections that affect up to 45 million people globally and are linked to bile duct cancer.
The PCR test detects 11 bacterial, viral, and parasitic pathogens from a stool sample in approximately 74 minutes.
A field-deployable test demonstrates high sensitivity in identifying low-level infections that traditional methods miss, potentially supporting elimination efforts.
University of Pittsburgh researchers develop a microneedle array sensor that delivers results in 10 minutes to tell if flu/COVID vaccines are effective.
The Liaison Plex Gastrointestinal Flex Assay detects 24 targets and offers broad parasite coverage with pay-per-target flexibility.
Monash University study finds different testing algorithms work best for pregnant women versus men who have sex with men.